Physician profile
Thomas Kincade
NPI 1376645325
$2,647.31
in general payments reported to CMS, 2019-2025
21 companies · $335 in 2025
The $335 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $295 · 2021: $334 · 2022: $330 · 2023: $546 · 2024: $344 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,225.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $491.58 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $487.88 | 2019-2023 | |
| Allergan, INC. | $343.05 | 2019-2022 | |
| Oyster Point Pharma, INC. | $237.70 | 2022-2025 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $143.07 | 2019-2021 | |
| Shire North American Group INC | $132.06 | 2019 | |
| Bausch & Lomb Americas INC. | $127.02 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Eyevance Pharmaceuticals LLC | $126.76 | 2019-2023 | Flarex |
| Xeris Pharmaceuticals, INC. | $71.39 | 2023-2024 | Gvoke Hypopen |
| Dompe US, INC. | $69.72 | 2024-2025 | Oxervate |
| Sight Sciences, INC. | $65.24 | 2022-2023 | Tearcare System |
| Kala Pharmaceuticals, INC. | $60.94 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $50.73 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $50.16 | 2024-2025 | Eysuvis, Tryptyr |
| Mallinckrodt Hospital Products INC. | $41.41 | 2020-2023 | Acthar |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $34.71 | 2024 | Izervay |
| Johnson & Johnson Surgical Vision, INC. | $32.98 | 2020 | |
| Aerie Pharmaceuticals, INC. | $28.48 | 2020-2021 | |
| Thea Pharma INC. | $24.76 | 2023 | |
| Amgen INC. | $14.54 | 2020 | |
| Corcept Therapeutics | $13.13 | 2023 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kincade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.